2016 Fiscal Year Final Research Report
Elucidation of the mechanism of drug resistance in colorectal cancer by p62-Keap 1-Nrf2 pathway
| Project/Area Number |
26462006
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KOMATSU Masaaki 新潟大学, 医歯学系, 教授 (90356254)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 大腸癌 / 抗癌剤耐性 / NQO1 / KRAS |
|---|
| Outline of Final Research Achievements |
p62-Keap1-Nrf2 pathway induce the antioxidants like NQO1. In cancer cells, NQO1 confers resistance against anticancer agents. The aim of this study was to evaluate the association between NQO1 expression and prognosis in patients with advanced colorectal cancer (CRC). Among the patients with KRAS wild CRC, NQO1-negative patients showed significantly better disease control rate than NQO1-positive patients. Moreover, NQO1-negative patients had longer progression-free survival and overall survival than NQO1-positive patients. NQO1 expression in the tumor may be a predictor of therapeutic efficacy and prognosis in patients with KRAS wild advanced CRC.
|
| Free Research Field |
大腸癌
|
